United Therapeutics
Clinical trials sponsored by United Therapeutics, explained in plain language.
Develops therapies for pulmonary arterial hypertension and other chronic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for PAH patients: Long-Term drug safety trial opens Results expected Dec 2026 (estimated) May already have reported ↗
- New registry follows PAH patients on orenitram in Real-World settings Results expected Mar 2027 (estimated)
-
New drug aims to help lungs and heart work better during exercise
Disease control Stopped earlyThis phase 3 trial tests whether ralinepag, an oral medication, can improve exercise capacity in people with pulmonary arterial hypertension (PAH) who have recently started PAH therapy. Participants take ralinepag or a placebo for 28 weeks, and their peak oxygen consumption durin…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Inhaled treprostinil safety trial for PH-COPD ends early
Disease control Stopped earlyThis study looked at the long-term safety of an inhaled drug called treprostinil in people who have both pulmonary hypertension (high blood pressure in the lungs) and COPD. It included 41 adults who had already completed a previous study. The trial was terminated early, and the m…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC